Navigation Links
Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Financial Results
Date:3/7/2013

incurred during the fourth quarter of 2012 as compared to the same period in 2011. For the twelve months ended December 31, 2012, selling, general and administrative expenses increased by $5.3 million to $86.8 million, from $81.5 million for 2011. This increase was mostly attributable to additional legal costs incurred in 2012 related to the company's ongoing intellectual property litigation, increased commissions earned by Cadence's hospital sales specialists as a result of higher sales levels, and additional costs incurred in connection with product distribution and related services. These increases were partially offset by lower medical affairs and marketing costs.  

As of December 31, 2012, Cadence reported cash, cash equivalents and short-term investments of $62.1 million. This figure does not include the $14.6 million of cash received by the company in early January 2013 in connection with the waiver of its option to acquire Incline and the sale of its shares of Incline stock. Net accounts receivable at December 31, 2012, was $6.2 million.

GuidanceAs of March 7, 2013, Cadence expects that net product revenue from sales of OFIRMEV for the twelve months ending December 31, 2013, will range from $94.0 million to $100.0 million.

Conference Call and Webcast on March 7, 2013 at 5:30 a.m. Pacific Time (8:30 a.m. Eastern Time) Cadence management will host a conference call on March 7, 2013, at 5:30 a.m. Pacific Time (8:30 a.m. Eastern Time) and interested investors may participate in the conference call by dialing (877) 303-9145 (domestic) or (760) 536-5203 (international). To access the webcast, please visit the company's website at www.cadencepharm.com and go to the Investors page. A replay of the webcast will be available approximately two hours after the call and remain available on the company's website until the next quarterly financial results call. Cadence uses the Investors portion of
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Fourth Quarter And Full Year 2012 Financial Results On March 7, 2013
2. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Cowen & Company 33rd Annual Health Care Conference In Boston On March 5, 2013
3. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Leerink Swann Global Healthcare Conference In New York City On February 13, 2013
4. Cadence Pharmaceuticals Estimates Fourth Quarter 2012 Net Product Revenue and Provides Full Year 2013 Revenue Guidance
5. Cadence Pharmaceuticals Announces Termination of Option Agreement to Acquire Incline Therapeutics, Inc.
6. Cadence Pharmaceuticals to Host Analyst and Investor Day
7. Cadence to Open Finished Medical Device Facility
8. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Piper Jaffray 24th Annual Healthcare Conference In New York City On November 28, 2012
9. Cadence Pharmaceuticals Reports Third Quarter 2012 Financial Results
10. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Third Quarter 2012 Financial Results On November 5, 2012
11. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Stifel Nicolaus Healthcare Conference 2012 In Boston On September 5, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... 21, 2014 Research and Markets  has announced ... Industry Report, 2014-2017" report to their offering. ... Chinese recombinant protein drug market has been expanding rapidly ... and the like. During 2005-2013, sales of recombinant protein ... CAGR of 19.1%, and it is projected that ...
(Date:11/21/2014)... Calif. and VIENNA, Va. ... innovative in-home care provider that operates in ... a leading provider of remote caregiving technology. Alta will ... and existing client receiving homecare services. Logo ... this technology is the key to providing the kind ...
(Date:11/21/2014)... 21, 2014  World Hemp Oil, an importer of ... they are now offering legal, organic oil with high ... strains grown in medical marijuana states. People suffering from ... as Parkinson,s, MS, and spinal cord injury, no longer ... because imported CBD Oil Is legal in all states. ...
Breaking Medicine Technology:China Recombinant Protein Drug Industry Report, 2014-2017 2China Recombinant Protein Drug Industry Report, 2014-2017 3Alta Home Care, Inc. and BeClose Partner to Enable Seniors to Remain in Their Homes Safely and Securely 2New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 2New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 3
... Confirm Tapentadol Efficacy and Tolerability for Acute Pain PatientsRARITAN, ... to 30 percent of all people who have surgery ... The use of opioid pain medicines during and after ... side effects. Nausea and vomiting are uncomfortable and bothersome ...
... Call to be Held at 9:00 a.m. Eastern Time ... United Therapeutics Corporation (Nasdaq: UTHR ) announced ... (FDA) has approved ADCIRCA(TM) (tadalafil) tablets for oral administration, ... first once-daily phosphodiesterase type 5 (PDE5) inhibitor for the ...
Cached Medicine Technology:New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal 2New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal 3New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal 4New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal 5New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal 6New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal 7New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal 8FDA Approves ADCIRCA(TM) (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension 2FDA Approves ADCIRCA(TM) (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension 3FDA Approves ADCIRCA(TM) (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension 4
(Date:11/22/2014)... 22, 2014 Discount-Dress.com is an ... the firm is to increase the company’s online market share ... new selection of bridesmaid dresses and announced a bridesmaid dress ... valid until Dec. 30, 2014. All the dresses from this ... , In fact, Discount-Dress.com is very good at manufacturing ...
(Date:11/22/2014)... Nocturia is defined by the International ... individual has to wake at night one or ... Pipeline Review, H2 2014” provides comprehensive information on ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ...
(Date:11/22/2014)... 2014 A petition seeking a ban ... in minimally-invasive hysterectomies and fibroid removal surgeries has ... of October, Bernstein Liebhard LLP reports. According to ... November 21st, 2014. That represents an increase of 456 ... on to the campaign.* , The campaign to ban ...
(Date:11/22/2014)... (HealthDay News) -- The wide variety and complexity of ... for people with food allergies, an expert warns. ... types of food allergies that it can be really ... Guha Krishnaswamy, director of allergy and clinical immunology at ... news release. "If you know you have food ...
(Date:11/22/2014)... New York, New York (PRWEB) November 22, 2014 ... been filed on behalf of patients who allegedly developed ... move forward in the federal multidistrict litigation now underway ... Liebhard LLP reports. According to court documents, the litigation ... at 10:00 a.m. The Court has directed Lead Counsel ...
Breaking Medicine News(10 mins):Health News:Bridesmaid Dresses Introduced by Famous Company Discount-Dress.com For The New Year 2015 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 4Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 2Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 3Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 4Health News:'Tis the Season of Challenges for Those With Food Allergies 2Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 3
... Valley Credits Outsourcing Support as Contributor to Profit Gain ... CSC (NYSE: CSC ) today announced ... business process outsourcing (BPO) services for Aspen Valley Hospital ... disclosed.Under the new agreement, CSC will continue to provide ...
... AMERIGROUP Corporation (NYSE: AGP ) announced today ... Nevada began offering healthcare services to individuals enrolled in ... beginning February 1, 2009. "We,re pleased to begin serving ... Carlson, AMERIGROUP Chairman and Chief Executive Officer. "We ...
... in your fridge, chances are you,ll try it, experts say , , ... that expired yogurt at the back of the fridge? What about ... , If you,re like most Americans, you,ll take the chance, a ... people would quickly reject at the supermarket are much more eagerly ...
... Feb. 2 Despite increasingly dire economic news ... where demand for candidates far exceeds supply. Rehabilitation ... professionals among healthcare staffing agencies and medical facilities. ... employment slowdown, that is not the case for ...
... Feb. 2 EDI Health Group, Inc. (EHG), ... for patients, payers and providers in the dental ... (Nasdaq: QSII ) to serve as ... Division (QSI) and its providers and payers. , ...
... from celiac diseaseANN ARBOR, Mich., Feb. 2 Dorothy Carpenter ... a bite of bread or pasta could lead to terrible ... of Michigan Health System physician recognized it as celiac ... mass, a cancer that forced doctors to remove part of ...
Cached Medicine News:Health News:CSC Signs Five-Year Outsourcing Extension With Aspen Valley Hospital 2Health News:AMERIGROUP Health Plan in Nevada Begins Serving Medicaid Enrollees 2Health News:You Own It, You'll Eat It 2Health News:You Own It, You'll Eat It 3Health News:Need for Traveling Therapists Boosts Demand for Lead Services of AlliedTravelCareers.com 2Health News:EDI Health Group Selected by Quality Systems to Facilitate EDI Transactions Between Payers and Large Dental Group Practices 2Health News:EDI Health Group Selected by Quality Systems to Facilitate EDI Transactions Between Payers and Large Dental Group Practices 3Health News:GI Condition Once Thought Rare is Common in U.S. 2Health News:GI Condition Once Thought Rare is Common in U.S. 3
The Cellabs Rapimal (P.f.) is a rapid and sensitive in vitro immunochromatography assay system for the detection of HRP-2 antigen produced by P. falciparum at the merozoite (red blood cell) stage o...
Malaria device / strip (3 line, PAN-pLDH, P.f.-HRP2)...
High sensitive, specific one step immunochromatographic assay for human infectious disease...
High sensitive, specific one step immunochromatographic assay for human infectious disease...
Medicine Products: